Our location
Geleen – new mRNA/LNP services and manufacturing
At our site in Geleen, Lonza operates cell and gene therapy process development and manufacturing, mRNA/LNP process and analytical development labs, as well as clinical cGMP capabilities. The facility includes more than 30,000 square feet of laboratory, cGMP manufacturing and office space. The expansion supports the manufacturing of non-GMP product suitable for formulation development and toxicology studies, as well as cGMP product for early and late-stage clinical trials. The expanded development services at the Geleen (NL) site are available with cGMP readiness scheduled in the first quarter 2024.
We build scalability into mRNA process development from the outset using platform technologies and standardized processes. Our approach ensures a smooth transition from small-scale laboratory development to large-scale cGMP manufacturing, minimizing the need for costly late-stage process changes.
We optimize the IVT process by carefully controlling template design, enzymatic reactions, and purification processes. This mRNA process development work supports high yields while maintaining the integrity, purity, and consistency therapeutic applications require.
We ensure reproducibility through robust process design, scalable platforms, and thorough process characterization. By utilizing standardized protocols and in-process controls during LNP process development, we enable consistent product performance across all production scales.
Focusing on early mRNA encapsulation process development allows us to define critical quality attributes and ensure product consistency, which are vital for clinical performance. This proactive approach reduces scale-up risks and supports a smoother, faster progression through regulatory milestones.
